{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:43:22Z","timestamp":1784249002296,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T00:00:00Z","timestamp":1690070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Buddhist Tzu Chi Medical Foundation","award":["TCRD-111-80"],"award-info":[{"award-number":["TCRD-111-80"]}]},{"name":"Buddhist Tzu Chi Medical Foundation","award":["TCMF-EP 111-01"],"award-info":[{"award-number":["TCMF-EP 111-01"]}]},{"name":"Buddhist Tzu Chi Medical Foundation","award":["TCRD 111-057"],"award-info":[{"award-number":["TCRD 111-057"]}]},{"name":"Buddhist Tzu Chi Medical Foundation","award":["TCMF-CP 111-05"],"award-info":[{"award-number":["TCMF-CP 111-05"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This study investigated the effects of progesterone receptors A (PRA) and B (PRB) on proliferation, migration, invasion, anchorage-independent growth (AIG), and apoptosis of FE25 cells, a precancer p53- and retinoblastoma-defective human fallopian tube epithelial cell line. We observed that the transfection of PRA (FE25-PRA) or PRB (FE25-PRB) into FE25 cells significantly increased the expression of PRA or PRB at both RNA and protein levels without affecting cell morphology. The FE25-PRA cells exhibited slower proliferation, whereas FE25-PRB showed faster cell proliferation than the control cells. In contrast, the FE25-PRA cells showed the highest migration and invasion abilities, whereas the FE25-PRB cells showed the lowest migration and invasion abilities. After treatment with progesterone, all cell types showed decreased AIG levels, increased apoptotic rates in Terminal deoxynucleotidyl transferase (TdT) dUTP nick end labeling assay (TUNEL) staining, and increased levels of apoptotic proteins ascertained based on cleaved caspase-3 levels. The half-maximal inhibitory concentration of carboplatin increased in FE25-PRB cells, but that of paclitaxel remained unchanged. Overall, this study suggests that PRA and PRB have distinct roles in regulating the behavior of FE25 cells, and targeting these receptors could be a potential therapeutic strategy for ovarian cancer treatment. If PRA or PRB overexpression is observed in high-grade serous carcinoma, progesterone could be considered as an adjuvant therapy for these specific cancer patients. However, further research is needed to confirm these findings and investigate the mechanisms underlying these effects.<\/jats:p>","DOI":"10.3390\/ijms241411823","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:47:03Z","timestamp":1690159623000},"page":"11823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of the Overexpression of Progesterone Receptors on a Precancer p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line"],"prefix":"10.3390","volume":"24","author":[{"given":"Yu-Hsun","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Chi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1429-2713","authenticated-orcid":false,"given":"Kai-Hung","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-068X","authenticated-orcid":false,"given":"Dah-Ching","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"},{"name":"Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Luo, G., Li, M., Guo, P., Xiao, Y., Ji, H., and Hao, Y. (2019). Global Patterns and Trends in Ovarian Cancer Incidence: Age, Period and Birth Cohort Analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6139-6"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Huang, J., Chan, W.C., Ngai, C.H., Lok, V., Zhang, L., Lucero-Prisno, D.E., Xu, W., Zheng, Z.-J., Elcarte, E., and Withers, M. (2022). Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers, 14.","DOI":"10.3390\/cancers14092230"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of Ovarian Cancer: A Review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"ref_4","first-page":"339","article-title":"Using PARP Inhibitors in Advanced Ovarian Cancer","volume":"32","year":"2018","journal-title":"Oncology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) Polymerase Inhibitor Olaparib in Patients with BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer: A Proof-of-Concept Trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1758834016687254","article-title":"PARP Inhibitors in Ovarian Cancer: Evidence, Experience and Clinical Potential","volume":"9","author":"Evans","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lin, H., Lan, K.-C., Ou, Y.-C., Wu, C.-H., Kang, H.-Y., Chuang, I.-C., and Fu, H.-C. (2021). Highly Expressed Progesterone Receptor B Isoform Increases Platinum Sensitivity and Survival of Ovarian High-Grade Serous Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13215578"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3892\/or.2021.8174","article-title":"Hormone Therapy for Ovarian Cancer: Emphasis on Mechanisms and Applications (Review)","volume":"46","author":"Li","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1091\/mbc.e12-11-0807","article-title":"Progesterone Receptor Isoforms PRA and PRB Differentially Contribute to Breast Cancer Cell Migration through Interaction with Focal Adhesion Kinase Complexes","volume":"24","author":"Bellance","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/bcr450","article-title":"Expression and Transcriptional Activity of Progesterone Receptor A and Progesterone Receptor B in Mammalian Cells","volume":"4","author":"Graham","year":"2002","journal-title":"Breast Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lenhard, M., Tereza, L., Heublein, S., Ditsch, N., Himsl, I., Mayr, D., Friese, K., and Jeschke, U. (2012). Steroid Hormone Receptor Expression in Ovarian Cancer: Progesterone Receptor B as Prognostic Marker for Patient Survival. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-553"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1073\/pnas.96.10.5722","article-title":"Expression of Human Estrogen Receptor-\u03b1 and -\u03b2, Progesterone Receptor, and Androgen Receptor mRNA in Normal and Malignant Ovarian Epithelial Cells","volume":"96","author":"Lau","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.11604\/pamj.2017.27.259.11883","article-title":"Hormone-Receptor Expression Status of Epithelial Ovarian Cancer in Ibadan, South-Western Nigeria","volume":"27","author":"Ajani","year":"2017","journal-title":"Pan Afr. Med. J."},{"key":"ref_16","first-page":"1827","article-title":"Loss of Progesterone Receptor through Epigenetic Regulation Is Associated with Poor Prognosis in Solid Tumors","volume":"10","author":"Li","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-Receptor Expression and Ovarian Cancer Survival: An Ovarian Tumor Tissue Analysis Consortium Study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_18","first-page":"221","article-title":"Decreased Progesterone Receptor Isoform Expression in Luteal Phase Fallopian Tube Epithelium and High-Grade Serous Carcinoma","volume":"18","author":"Tone","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/jog.12519","article-title":"Polymorphisms of Progesterone Receptor and Ovarian Cancer Risk: A Systemic Review and Meta-Analysis","volume":"41","author":"Liao","year":"2015","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.tcmj.2013.04.002","article-title":"The Fallopian Tube Is the Culprit and an Accomplice in Type II Ovarian Cancer: A Review","volume":"25","author":"Hong","year":"2013","journal-title":"Tzu Chi Med. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/carcin\/bgv132","article-title":"Mutagenic, Surviving and Tumorigenic Effects of Follicular Fluid in the Context of p53 Loss: Initiation of Fimbria Carcinogenesis","volume":"36","author":"Huang","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chang, Y.-H., Chu, T.-Y., and Ding, D.-C. (2022). Spontaneous Transformation of a p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line after Long Passage with Features of High-Grade Serous Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213843"},{"key":"ref_24","first-page":"53","article-title":"Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification","volume":"4","author":"Gracanin","year":"2017","journal-title":"Front. Vet. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Khan, J.A., Bellance, C., Guiochon-Mantel, A., Lomb\u00e8s, M., and Loosfelt, H. (2012). Differential Regulation of Breast Cancer-Associated Genes by Progesterone Receptor Isoforms PRA and PRB in a New Bi-Inducible Breast Cancer Cell Line. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0045993"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11711","DOI":"10.1093\/nar\/gkx781","article-title":"The Stability of an mRNA Is Influenced by Its Concentration: A Potential Physical Mechanism to Regulate Gene Expression","volume":"45","author":"Nouaille","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mce.2011.09.016","article-title":"Progesterone Receptors, Their Isoforms and Progesterone Regulated Transcription","volume":"357","author":"Jacobsen","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/aji.12473","article-title":"Progesterone-Regulated Endometrial Factors Controlling Implantation","volume":"75","author":"Bhurke","year":"2016","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cope, D.I., and Monsivais, D. (2022). Progesterone Receptor Signaling in the Uterus Is Essential for Pregnancy Success. Cells, 11.","DOI":"10.3390\/cells11091474"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e009","DOI":"10.1621\/nrs.07009","article-title":"Progesterone Action in Human Tissues: Regulation by Progesterone Receptor (PR) Isoform Expression, Nuclear Positioning and Coregulator Expression","volume":"7","author":"Scarpin","year":"2009","journal-title":"Nucl. Recept. Signal."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevEukarGeneExpr.v18.i1.20","article-title":"Progesterone Receptor Isoform Functions in Normal Breast Development and Breast Cancer","volume":"18","author":"Kariagina","year":"2008","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1369\/jhc.2009.954644","article-title":"Immunocytochemical Localization of Sex Steroid Hormone Receptors in Normal Human Mammary Gland","volume":"58","author":"Li","year":"2010","journal-title":"J. Histochem. Cytochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fendo.2019.00198","article-title":"Progesterone-Related Immune Modulation of Pregnancy and Labor","volume":"10","author":"Shah","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13048-019-0486-4","article-title":"Progesterone Reduces Cell Survival in Primary Cultures of Endometrioid Ovarian Cancer","volume":"12","author":"Pedernera","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41379-019-0370-1","article-title":"Natural History of Ovarian High-Grade Serous Carcinoma from Time Effects of Ovulation Inhibition and Progesterone Clearance of p53-Defective Lesions","volume":"33","author":"Wu","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.celrep.2017.02.049","article-title":"Progesterone Prevents High-Grade Serous Ovarian Cancer by Inducing Necroptosis of p53-Defective Fallopian Tube Epithelial Cells","volume":"18","author":"Wu","year":"2017","journal-title":"Cell Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31993","DOI":"10.1073\/pnas.2013595117","article-title":"Targeting Progesterone Signaling Prevents Metastatic Ovarian Cancer","volume":"117","author":"Kim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ygyno.2004.11.010","article-title":"Expression of Progesterone Receptor Is a Favorable Prognostic Marker in Ovarian Cancer","volume":"96","author":"Lee","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1349-7006.2002.tb01323.x","article-title":"Differential Expression of Progesterone Receptor Isoforms A and B in the Normal Ovary, and in Benign, Borderline, and Malignant Ovarian Tumors","volume":"93","author":"Akahira","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"33146","DOI":"10.18632\/oncotarget.5082","article-title":"Role of the Short Isoform of the Progesterone Receptor in Breast Cancer Cell Invasiveness at Estrogen and Progesterone Levels in the Pre- and Post-Menopausal Ranges","volume":"6","author":"McFall","year":"2015","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2008.12.032","article-title":"Induction of Senescence by Progesterone Receptor-B Activation in Response to cAMP in Ovarian Cancer Cells","volume":"113","author":"Takahashi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-14-0252","article-title":"Progesterone Action in Breast, Uterine, and Ovarian Cancers","volume":"54","author":"Diep","year":"2015","journal-title":"J. Mol. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(22)00283-2","article-title":"Weekly Dose-Dense Chemotherapy in First-Line Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Treatment (ICON8): Overall Survival Results from an Open-Label, Randomised, Controlled, Phase 3 Trial","volume":"23","author":"Clamp","year":"2022","journal-title":"Lancet Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:17:28Z","timestamp":1760127448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,23]]},"references-count":43,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411823"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411823","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,23]]}}}